Phase I study of paclitaxel (taxol™) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer: A study of the National Cancer Institute of Canada clinical trials group

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 311-313

  Shepherd, F A ^a,e   Latreille, J ^b   Crump, M ^a   Stewart, D ^c   Tomiak, E ^c   Eisenhauer, E ^d   Fisher, B ^d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Ottawa Mindfulness Clinic   (Canada)

^d Queen's Cancer Research Institute   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy; Ifosfamide; Non small cell lung cancer; Paclitaxel

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; IFOSFAMIDE; MESNA; PACLITAXEL; SEROTONIN ANTAGONIST;

ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DRUG HYPERSENSITIVITY; FEMALE; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0029922469     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010577     Document Type: Article

References (9)

1. Ettinger DS. Overview of paclitaxel (Taxol®) in advanced lung cancer. Semin Oncol 1993; 20 (Suppl 3): 46-9.
2. Chang A, Kim K, Glick T et al. Phase II study of Taxol in patients with stage IV non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992; 11: 293 (Abstr).
3. Murphy WK, Winn RJ, Fossella FV et al. A phase II study of Taxol in patients with stage IV study of Taxol in patients with stage IV non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992; 11: 294 (Abstr).
4. Johnson DH. Overview of ifosfamide in small cell and non-small-cell lung cancer. Semin Oncol 1990; 17 (Suppl 4): 24-34.
5. Eberhart W, Niederle N. Ifosfamide in non-small-cell lung cancerz: A review. Semin Oncol 1992; 19 (Suppl 1): 40-8.
6. Postma TJ, Vermorken JB, Liefting AJM et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94.
7. Schiller JH, Storer B, Tutsch K et al. Phase I trial of 3-hour paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241-8.
8. Hoffman PC, Krauss SA, Drinkard LC et al. Paclitaxel and ifosphamide: A multi-center phase 1 study in advanced non-small-cell lung cancer. Semin Oncol 1995; 22 (Suppl 9): 38-41.
9. Eisenhauer EA, Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.